Director of REMEDI
Development of gene and cell therapy approaches to vascular disease with a special focus on the augmentation of nitric oxide bioavailability.
Researcher in
Professor O'Brien established the Regenerative Medicine Institute at NUI, Galway (REMEDI). The focus of the Institute is to exploit the synergies between the technologies of gene delivery and stem cell biology to promote organ regeneration and repair. The principal initial disease targets of the Institute are ischaemic cardiovascular disease and osteoarthritis.
NO bioavailability
NO bioavailability is diminished in a variety of vascular disease states such as hypertension, hyperlipidemia and diabetic wounds. Prof. O'Brien is interested in a therapeutic approach to these disorders using gene and or cell therapy. The gene therapy approach has focused on targeted expression of nitric oxide isoforms in the diseased vessel site and the use of endothelial progenitor cells as a gene delivery system. Prof. O'Brien also has an interest in the pathogenesis of diabetic vascular disease including the role of endothelial progenitor cell dysfunction.
2004-present
Director of the Regenerative Medicine Institute, NUI, Galway and GUH
2001- present
Professor and Head of Medicine, Consultant Endocrinologist
NUIG and Galway University Hospital
1995-2001
Consultant
Division of Endocrinology, Nutrition and Metabolism, Mayo Clinic, Rochester, Minnesota, USA
1999-2001
Associate Professor of Medicine
Mayo Foundation, Rochester, Minnesota, USA
1995-1999
Assistant Professor of Medicine
Mayo Graduate School of Medicine, Rochester, MN, USA
1993-1994
Postdoctoral Fellow
Gladstone Institute of Cardiovascular Disease, San Francisco
1993-1994
Assistant Clinical Professor of Medicine
University of California, San Francisco, USA
1990-1992
Fellow in Endocrinology and Metabolism
Mayo Graduate School of Medicine, Rochester, MN, USA
1988-1990
Resident in Internal Medicine
Medical College of Wisconsin, Milwaukee, WI, USA
1984-1988
Resident in Internal Medicine
Cork Regional Hospital
Education/Qualifications
1996
Ph.D
National University of Ireland, Cork
1990
M.D
National University of Ireland, Cork
1987
MRCP (UK)
Royal College of Physicians, UK
1986
MRCPI Part 2
Royal College of Physicians of Ireland
1986
MRCPI Part 1
Royal College of Physicians of Ireland
1978
College Scholar; University College Cork
1988
Ainsworth Scholarship; University College Cork
1991-1992
WL Stephenson Fellowship in Clinical Nutrition; Mayo Graduate School of Medicine
1993-1994
Mayo Foundation Scholar; Mayo Graduate School of Medicine
1993
Sprague Award for Excellence in Clinical Medicine; Division of Endocrinology and Metabolism, Mayo Clinic
1997
Outstanding Poster Presentation. Internal Medicine Research Activities Forum, Mayo Clinic
1998
Young Investigator Award. Vascular and Myocardial Aspects of Ischemic Heart Disease. American Heart Association.
1998
Mayo Clinic Internal Medicine Research Award: Adipocyte Macrophage Colony Stimulating Factor (MCSF) Is a mediator of adipose tissue growth.
2005
Stokes Medal, Irish Cardiac Society
2007
Nordisk Lecture, Irish Endocrine Society
2008
48th Graves lecture of the Royal academy of Medicine in Ireland
2009 Mayne Lecture, Trinity College Dublin (TCD)
PubMed Link: http://www.ncbi.nlm.nih.gov/pubmed?term=O'Brien%20T%20Galway
Khurana VG
Zanetti M
Sato J
Cable DG
Onoue H
Levine JA
Kullo IJ
Kullo IJ
Chen AFY
Chen AF
Recent Publications
Reeve
Reeve JL
Dwyer RM
Stender S
Rao
Rooney
Sen S
Sharif F
Mohr A
Rooney
Breen
Mylotte LA
Breen
Gilbert
Molloy AP
Breen A
Kealy
MacLoughlin
Duffy GP
Rooney
Kulkarni M
Rooney GE
O’Loughlin A
Halloday C
Kulkarni M
Madsen D
McMahon SS
O’Toole D
Eglon M
Madigan NN
Kubiak C
O'Shea CA, Hynes SO, Shaw G, Coen BA, Hynes AC, McMahon J, Murphy M, Barry F, O'Brien T. Bolus delivery of mesenchymal stem cells to injured vasculature in the rabbit carotid artery produces a dysfunctional endothelium. Tissue Eng Part A. 2010 May;16(5):1657-65.
Duffy AM, O'Brien T, McMahon JM. Generation of antioxidant adenovirus gene transfer vectors encoding CuZnSOD, MnSOD, and catalase. Methods Mol Biol. 2010;594:381-93.
Eglon M, McGrath B, O'Brien T. HPLC purification of adenoviral vectors. Methods Mol Biol. 2010;594:395-408. PMID:20072933
McMahon SS, Albermann S, Rooney GE, Shaw G, Garcia Y, Sweeney E, Hynes J, Dockery P, O'Brien T, Windebank AJ, Allsopp TE, Barry FP. Engraftment, migration and differentiation of neural stem cells in the rat spinal cord following contusion injury. Cytotherapy. 2010 May;12(3):313-25.
Duffy GP, D'Arcy S, Ahsan T, Nerem RM, O'Brien T, Barry F.Mesenchymal stem cells overexpressing ephrin-b2 rapidly adopt an early endothelial phenotype with simultaneous reduction of osteogenic potential. Tissue Eng Part A. 2010 Sep;16(9):2755-68.
Donnelly EM, Strappe PM, McGinley LM, Madigan NN, Geurts E, Rooney GE, Windebank AJ, Fraher J, Dockery P, O'Brien T, McMahon SS. Lentiviral vector-mediated knockdown of the neuroglycan 2 proteoglycan or expression of neurotrophin-3 promotes neurite outgrowth in a cell culture model of the glial scar. J Gene Med. 2010 Nov;12(11):863-72. doi: 10.1002/jgm.1509. Epub 2010 Oct 26.
Hoare M
Hynes SO, McCabe C, O'Brien T. β cell protection by inhibition of iNOS through lentiviral vector-based strategies. Methods Mol Biol. 2011;704:153-68. PMID:21161636
Kulkarni MM, Greiser U, O'Brien T, Pandit A. A Temporal Gene Delivery System Based on Fibrin Microspheres. Mol Pharm. 2011 Jan 12. [Epub ahead of print] PMID:21171649
Flynn A, O'Brien T. Stem cell therapy for cardiac disease. Expert Opin Biol Ther. 2011 Feb;11(2):177-87. PMID:21219235
Holladay C, Power K, Sefton M, O'Brien T, Gallagher WM, Pandit A. Functionalized Scaffold-mediated Interleukin 10 Gene Delivery Significantly Improves Survival Rates of Stem Cells In Vivo. Mol Ther. 2011 Jan 25. [Epub ahead of print]PMID:21266957
Heneghan HM, Miller N, McAnena OJ, O'Brien T, Kerin MJ. Differential miRNA Expression in Omental Adipose Tissue and in the Circulation of Obese Patients Identifies Novel Metabolic Biomarkers. J Clin Endocrinol Metab. 2011 Mar 2. [Epub ahead of print] PMID: 21367929
Dwyer RM, Ryan J, Havelin RJ, Morris JC, Miller BW, Liu Z, Flavin R, O'Flatharta C, Foley MJ, Barrett HH, Murphy JM, Barry FP, O'Brien T, Kerin MJ. Mesenchymal Stem Cell (Msc) Mediated Delivery of the Sodium Iodide Symporter (Nis) Supports Radionuclide Imaging and Treatment of Breast Cancer. Stem Cells. 2011 May 23. doi: 10.1002/stem.665. [Epub ahead of print] PMID: 21608083
Recent Review Articles
Liew, A, McDermott, J.H, Barry, F, O’Brien, T. Endothelial progenitor cells for the treatment of diabetic vasculopathy: panacea or pandora’s box? Diabetes Obes Metab. 2007 Sep 6;.
Gaffney, MM, Hynes, SO, Barry, F, O’Brien, T. Cardiovascular gene therapy: current status and therapeutic potential. British journal of Pharmacology (2007) 152, 175-188. This article was downloaded (either in pdf or html form) a total of 1,857 times by online subscribers over the 3 months post-publication, the largest number of downloads of all the papers in this issue of BJP.
Flynn A, Barry F, O’Brien T. UC-blood derived mesenchymal stromal cells: an overview. Cytotherapy 9(8):7127-726 Oct 2007.
McCabe C, O’Brien T. The rational design of beta cell cytoprotective gene transfer strategies: targeting deleterious iNOS expression. Mol Biotechnol 37(1):33-47 Sep 2007.
Flynn, A, O’Brien, T. Alferminogene Tadenovac, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs 2008 11 (4): © The Thomson Corporation ISSN 1369-7056.
Holladay CA, O'Brien T, Pandit A. Non-viral gene therapy for myocardial engineering. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 May-Jun;2(3):232-48. Review. PMID:20063367
Mieske K, Flaherty G, O'Brien T. Journeys to high altitude--risks and recommendations for travelers with preexisting medical conditions.J Travel Med. 2010 Jan-Feb;17(1):48-62. Review.
Griffin M, Greiser U, Barry F, O'Brien T, Ritter T. Genetically modified mesenchymal stem cells and their clinical potential in acute cardiovascular disease. Discov Med. 2010 Mar;9(46):219-23. Review. PMID:203504886
O'Loughlin A, McIntosh C, Dinneen SF, O'Brien T. Review paper: basic concepts to novel therapies: a review of the diabetic foot. Int J Low Extrem Wounds. 2010 Jun;9(2):90-102. Review. PMID:20483808
Moran CJ, Shannon FJ, Barry FP, O'Byrne JM, O'Brien T, Curtin W. Translation of science to surgery: linking emerging concepts in biological cartilage repair to surgical intervention. J Bone Joint Surg Br. 2010 Sep;92(9):1195-202. Review.
Locke P, O'Brien T, Tuan RS. Stem Cell Research & Therapy marks its first anniversary. Stem Cell Res Ther. 2011 May 6;2(3):22. [Epub ahead of print] PMID: 21554748
Science Foundation Ireland: Principal Investigator for Regenerative Medicine Institue (REMEDI).
From Research to Human Therapy €7,456,432 – direct costs. 2010-2015.
Enterprise Ireland: PI Development of Liposomal Gene Transfer using a stent based platform. 2007-2010. €489,993.
Health Research Board: Co-investigator Regeneration of injured Spinal Cord Neurons through implantable polymer bridges. 2007-2010. €305,694.
Health Research Board: PI Genetic Engineering of Vein Grafts to prevent Restenosis. 2007-2010. €273,000.
European Union Framework 7 PurStem EU FP7: Utilisation of the mesenchymal stem cell receptome for rational development of uniform, serum-free culture conditions and tools for cell characterisation. 2008-2011. €1,111,960
Science Foundation Ireland: Systems Biology Ireland: A systems biology approach towards understanding mesenchymal stem cell migration. 2008-2012. €2,930,854.
Professional memberships:
- American College of Physicians
- American Medical Association
- American Diabetes Association
- American Association for the Advancement of Science
- American Federation of Clinical Research
- Royal College of Physicians of Ireland
- Arteriosclerosis Council of the American Heart Association
- American Society of Gene Therapy
- Irish Heart Foundation
- Editorial Board of Endocrine Practice and the Journal of Translational Medicine
- Editor-in-Chief of Stem Cell Research & Therapy - http://www.stemcellres.com
- North American Vascular Biology Association
- Scientific Editorial Board of Human Gene Therapy









